Semnur Pharmaceuticals, Inc. SEC filings SMNRW

Semnur Pharmaceuticals, Inc. has 221 filings in SEC EDGAR's recent list, going back to Mar 1, 2022. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Jul 7, 2026 (material agreement, unregistered share sale, regulation fd disclosure). The company's fiscal year ends on December 31.

Form Description Filed Period
DEF 14A Proxy statement Apr 30, 2026 Jun 25, 2026
DEFA14A Additional proxy material Aug 22, 2025 —
DEF 14A Proxy statement Mar 27, 2025 Apr 10, 2025
PRE 14A Preliminary proxy statement Mar 20, 2025 Mar 20, 2025
DEF 14A Proxy statement Jun 28, 2024 Jul 10, 2024
PRE 14A Preliminary proxy statement Jun 18, 2024 Jun 18, 2024
DEFA14A Additional proxy material Dec 29, 2023 —
DEFM14A Filing Dec 15, 2023 —
DEF 14A Proxy statement Sep 25, 2023 Oct 11, 2023
PRE 14A Preliminary proxy statement Sep 12, 2023 Sep 11, 2023

Showing 10 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
SMNR (OTC), SMNRW (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Palo Alto, CA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1913577
Former names
Denali Capital Acquisition Corp. (until Sep 23, 2025)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.